REHOVOT, Israel--(BUSINESS WIRE)--Biokine Therapeutics, Ltd. announced today that it has received a $1.2 million (NIS 5.25 million) research grant from the Office of the Chief Scientist of the Ministry of Industry, Trade and Labor of Israel. The funding will support a Phase I/IIa clinical study to test the safety and the efficacy of the company’s flagship product, BKT140 as a therapeutic treatment for myeloma and other hematological diseases. Biokine also announced today the initiation of this study at the Chaim Sheba Medical Center, Tel-Hashomer, Israel.
